Celsion Abstract Chosen for Oral Presentation in Award Session at IHPBA Congress in Mumbai, India

(BUSINESS WIRE) -- CELSION CORPORATION (AMEX: CLN: 2.83, -0.10, -3.41%) today announced that the company's ThermoDox liver cancer abstract, "Phase I Study of ThermoDox (Thermally Sensitive Liposomes Containing Doxorubicin) Given Prior to Radiofrequency Ablation for Unresectable Liver Cancers" has been selected for oral presentation in the Awards Session at the 8th Annual International Hepato-Pancreato-Bilary Association (IHPBA) Congress in Mumbai, India from February 27th to March 2nd. (http://www.ihpba2008.com/)
This Congress is hosted every two years at a different international location, with leading faculty and researchers invited from nearly 50 countries to provide global perspectives on the standard of care and latest treatment options for liver cancer. Of the over one thousand abstracts submitted to the Congress, only five percent were chosen for oral presentations in the Awards Session. The presentation will be made by Dr. Ronnie T. Poon, MD, Professor of Surgery, Faculty of Medicine at Queen Mary Hospital, University of Hong Kong.

full article >> http://www.foxbusiness.com/markets/industries/health-care/article/celsion-abstract-chosen-oral-presentation-award-session-ihpba-congress-mumbai_430519_10.html